SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)

CAPS Rating: 4 out of 5

A biopharmaceutical company, which is engaged in the development and commercialization of novel therapeutics to treat life-threatening diseases.


Player Avatar zzlangerhans (99.85) Submitted: 5/10/2011 9:22:14 PM : Underperform Start Price: $4.66 SCLN Score: +5.93

Seems like SciClone's share price keeps gravitating back up towards 5, despite unpredictability of future revenues due to an ongoing review of Zadaxin pricing by Chinese authorities, coincident investigations of the company by the SEC and US DOJ, and a faltering pipeline. Zadaxin revenues were actually down on a quarter-to-quarter basis. I'm neutral on the NovaMed purchase until there is more clarity on profit and the true price of the acquisition. I see the stock primed for a lovely haircut at this level when the inevitable negative catalyst emerges.

Report this Post 2 Replies
Member Avatar sybil50 (< 20) Submitted: 5/13/2011 3:59:31 PM
Recs: 0

I've noticed SciClone's progress with pleasant surprise as it rises in spite of its recent baggage - but I bought it not long ago when it was in the low 3's so I'm a happy camper right now. My plan of action is to watch closely and ditch a large part at the first sign of a dribble. (why so happy about gloom and doom?)

Member Avatar zzlangerhans (99.85) Submitted: 9/28/2011 1:36:30 PM
Recs: 0

How's the camping these days?

Featured Broker Partners